Should I buy or sell Verve Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERV shares. View VERV analyst ratings or view top-rated stocks .

What is Verve Therapeutics' stock price target for 2024?

8 Wall Street research analysts have issued 1 year price objectives for Verve Therapeutics' stock. Their VERV share price targets range from $15.00 to $55.00. On average, they expect the company's share price to reach $33.00 in the next year. This suggests a possible upside of 351.4% from the stock's current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts .

How have VERV shares performed in 2024?

Verve Therapeutics' stock was trading at $13.94 at the beginning of 2024. Since then, VERV stock has decreased by 47.6% and is now trading at $7.31. View the best growth stocks for 2024 here .

When is Verve Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VERV earnings forecast .

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) posted its earnings results on Tuesday, February, 27th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.14. The company had revenue of $5.14 million for the quarter, compared to the consensus estimate of $3.95 million. Verve Therapeutics had a negative net margin of 1,701.70% and a negative trailing twelve-month return on equity of 39.33%.

What ETFs hold Verve Therapeutics' stock?

ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , ARK Genomic Revolution ETF (ARKG) , Global X Genomics & Biotechnology ETF (GNOM) , Direxion Moonshot Innovators ETF (MOON) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) . ARK Innovation ETF (ARKK) .

When did Verve Therapeutics IPO?

Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Green Alpha Advisors LLC (0.03%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger , Andrew D Ashe , Burt A Adelman , Cormorant Asset Management, Lp, Fmr Llc, Joan Nickerson, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan . View institutional ownership trends .

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free VERV Stock Alerts

$7.31

-0.29 (-3.82%)

(As of 04/15/2024 ET)

Compare

Today's Range: $7.13
▼
$7.73
50-Day Range: $7.31
▼
$17.96
52-Week Range: $7.13
▼
$21.42

Volume: 1.37 million shs
Average Volume: 1.25 million shs
Market Capitalization: $611.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.00

Get Verve Therapeutics alerts:

Verve Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 351.4% Upside
$33.00 Price Target
Short Interest: Bearish
28.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.80
Based on 12 Articles This Week
Insider Trading: Selling Shares
$12,475 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.92) to ($2.87) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.23 out of 5 stars

Medical Sector

545th out of 929 stocks

Pharmaceutical Preparations Industry

248th out of 422 stocks

3.4

Analyst's Opinion

Consensus Rating
Verve Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Verve Therapeutics has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
28.03% of the float of Verve Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Verve Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Verve Therapeutics has recently increased by 8.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Verve Therapeutics does not currently pay a dividend.
Dividend Growth
Verve Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VERV.

3.2

News and Social Media Coverage

News Sentiment
Verve Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Verve Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 7 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.
MarketBeat Follows
7 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verve Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,475.00 in company stock.
Percentage Held by Insiders
21.40% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Verve Therapeutics are expected to grow in the coming year, from ($2.92) to ($2.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verve Therapeutics is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verve Therapeutics is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verve Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Verve Therapeutics Stock (NASDAQ:VERV)

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VERV Stock News Headlines

April 4, 2024 | insidertrades.com

Joan Nickerson Sells 1,514 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) Stock

April 13, 2024 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Shares Gap Up to $8.01

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

April 12, 2024 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down to $8.75

April 11, 2024 | benzinga.com

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

April 11, 2024 | americanbankingnews.com

Research Analysts Issue Forecasts for Verve Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:VERV)

April 9, 2024 | markets.businessinsider.com

Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery

April 9, 2024 | msn.com

A Bold Gene-Editing Solution Began Testing—Then Hit the Strangest Twist

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 9, 2024 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Receives New Coverage from Analysts at HC Wainwright

April 6, 2024 | fool.com

After a Serious Setback, Is Verve Therapeutics a Buy?

April 3, 2024 | msn.com

Gene Editing Experiment Halted as Patient Gets Weird Side Effects

April 3, 2024 | seekingalpha.com

Verve Therapeutics: An Update On Human CRISPR

April 3, 2024 | seekingalpha.com

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

April 2, 2024 | msn.com

Verve Therapeutics pauses enrollment of patients in trial for its gene therapy to treat high cholesterol after severe side effect

April 2, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Verve Therapeutics with Strategic Focus on Promising VERVE-102 Program

April 2, 2024 | bizjournals.com

Verve’s stock tumbles as biotech pauses gene editing trial over safety concerns

April 2, 2024 | marketwatch.com

Verve Therapeutics Pauses Enrollment in Trial of Gene Editing Medicine After Serious Adverse Event

April 2, 2024 | markets.businessinsider.com

Verve Therapeutics To Halt Enrollment In Heart-1 Phase 1b Trial Of VERVE-101; Stock Falls

April 2, 2024 | msn.com

Verve drops after pausing enrollments in trial for lead asset

April 2, 2024 | msn.com

Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback

April 2, 2024 | finance.yahoo.com

Verve Falls as Gene-Editing Trial Paused on Safety Issues

April 2, 2024 | finance.yahoo.com

Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects

April 2, 2024 | reuters.com

Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels

April 2, 2024 | globenewswire.com

Verve Therapeutics Announces Updates on its PCSK9 Program

March 28, 2024 | globenewswire.com

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 27, 2024 | msn.com

7 Best Gene-Editing Stocks to Invest in Right Now

See More Headlines

Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VERV
CUSIP: N/A
CIK: 1840574
Web: vervetx.com
Phone: 617-603-0070
Fax: N/A
Employees: 255
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.00
High Stock Price Target: $55.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +351.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-200,070,000.00
Net Margins: -1,701.70%
Pretax Margin: -1,699.21%
Return on Equity: -39.33%
Return on Assets: -30.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.24
Quick Ratio: 17.24

Sales & Book Value

Annual Sales: $11.76 million
Price / Sales: 51.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.31 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 83,620,000
Free Float: 65,725,000
Market Cap: $611.26 million
Optionable: Optionable
Beta: 1.70

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Burt A. Adelman M.D. (Age 72)
Co-Founder & Independent Chairman of the Board
Comp: $87.55k
Dr. Sekar Kathiresan M.D. (Age 52)
Co-Founder, CEO & Director
Comp: $899.55k
Mr. Andrew D. Ashe J.D. (Age 57)
President, COO & General Counsel
Comp: $703.85k
Dr. Andrew Bellinger M.D. (Age 45)
Ph.D., Chief Scientific Officer
Comp: $703.85k
Dr. Kiran Musunuru M.D.
M.P.H., Ph.D., Co-Founder
Dr. J. Keith Joung M.D.
Ph.D., Co-Founder
Dr. Anthony Philippakis M.D.
Ph.D., Co-Founder & Scientific Advisory Board Member
Dr. Barry S. Ticho FACC (Age 63)
M.D., Ph.D., Co-Founder
Mr. Issi Rozen M.B.A.
Co-Founder & Strategic Advisor
Ms. Allison Dorval (Age 48)
CFO & Principal Accounting Officer
Comp: $260.93k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VERV Stock Analysis - Frequently Asked Questions

Should I buy or sell Verve Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERV shares.
View VERV analyst ratings or view top-rated stocks.
What is Verve Therapeutics' stock price target for 2024?: 8 Wall Street research analysts have issued 1 year price objectives for Verve Therapeutics' stock. Their VERV share price targets range from $15.00 to $55.00. On average, they expect the company's share price to reach $33.00 in the next year. This suggests a possible upside of 351.4% from the stock's current price.
View analysts price targets for VERV or view top-rated stocks among Wall Street analysts.
How have VERV shares performed in 2024?: Verve Therapeutics' stock was trading at $13.94 at the beginning of 2024. Since then, VERV stock has decreased by 47.6% and is now trading at $7.31.
View the best growth stocks for 2024 here.
When is Verve Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our VERV earnings forecast.
How were Verve Therapeutics' earnings last quarter?: Verve Therapeutics, Inc. (NASDAQ:VERV) posted its earnings results on Tuesday, February, 27th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.14. The company had revenue of $5.14 million for the quarter, compared to the consensus estimate of $3.95 million. Verve Therapeutics had a negative net margin of 1,701.70% and a negative trailing twelve-month return on equity of 39.33%.

What ETFs hold Verve Therapeutics' stock?: ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), Direxion Moonshot Innovators ETF (MOON) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).ARK Innovation ETF (ARKK).
When did Verve Therapeutics IPO?: Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.
Who are Verve Therapeutics' major shareholders?: Verve Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Green Alpha Advisors LLC (0.03%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Joan Nickerson, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan.
View institutional ownership trends.
How do I buy shares of Verve Therapeutics?: Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERV) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Verve Therapeutics (VERV) Stock Price, News & Analysis

Verve Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Verve Therapeutics Stock (NASDAQ:VERV)

VERV Stock Price History

VERV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VERV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™